These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6139140)

  • 21. The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery.
    van der Starre PJ; Scheijgrond HW; Reneman RS; Kolling JB
    Anesth Analg; 1983 Jan; 62(1):63-9. PubMed ID: 6600382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina.
    Mata-Bourcart LA; Waters DD; Bouchard A; Miller DD; Théroux P
    Can J Cardiol; 1985; 1(3):168-71. PubMed ID: 2932205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is prevention of hypertension after open heart surgery possible by blocking 5HT2-receptors with ketanserin?
    van den Broeke JJ; Karliczek GF; Brenken U; Schokkenbroek R; Homan van der Heide JN
    Acta Anaesthesiol Belg; 1982; 33(2):115-20. PubMed ID: 6981913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of an oral serotonin antagonist, ketanserin, on plasma ACTH concentrations in Nelson's syndrome.
    Prescott RW; Ratcliffe WA; Taylor PK
    Br Med J (Clin Res Ed); 1984 Sep; 289(6448):787-8. PubMed ID: 6089950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension.
    Hamet A; Král B; Cernohorský D
    Cor Vasa; 1985; 27(6):406-11. PubMed ID: 2936568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
    Prostran M
    Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatment of claudication: vasodilators, hemorrheologic agents, and antiserotonin drugs.
    Taylor LM; Porter JM
    J Vasc Surg; 1986 Feb; 3(2):374-81. PubMed ID: 2935646
    [No Abstract]   [Full Text] [Related]  

  • 31. Endotoxin shock in the piglet: beneficial effects of serotonin antagonism.
    Schrauwen E; Weyns A; Houvenaghel A
    Br Vet J; 1985; 141(2):179-85. PubMed ID: 3158371
    [No Abstract]   [Full Text] [Related]  

  • 32. The 5-hydroxytryptamine antagonist ketanserin inhibits the vasoconstrictor activity of per-operative CSF, from subarachnoid haemorrhage patients, on isolated tissues.
    Tagari PC; Kaye AH; Teddy PJ; Schachter M; Adams CB; Boullin DJ
    J Neurol Neurosurg Psychiatry; 1983 Mar; 46(3):214-20. PubMed ID: 6188804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of antiserotonin treatment with ketanserin on the pulmonary lodgement of circulating tumour cells in normal and traumatized rats.
    Skolnik G; Ivarsson L; Bagge U
    Eur J Cancer Clin Oncol; 1983 Jun; 19(6):843-6. PubMed ID: 6683651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra arterial ketanserin in peripheral vascular disease.
    Boas RA
    Angiology; 1986 Apr; 37(4):267-71. PubMed ID: 2940946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.
    Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G
    Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173
    [No Abstract]   [Full Text] [Related]  

  • 36. Continuous imaging of regional blood flow in peripheral vascular disease using Krypton-81m: effect of Ketanserin, a new selective serotonin antagonist.
    Gerritsen HA; Perquin JW; de Smet HL; Troost FA; Kotora OV
    Diagn Imaging; 1983; 52(2-3):85-92. PubMed ID: 6851822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of serotonin-receptor blockade after cardiopulmonary by-pass. A pilot study.
    Miranda DR; Stoutenbeek CP; Zandstra D; Alexander JP
    Acta Anaesthesiol Belg; 1982; 33(1):63-8. PubMed ID: 7090727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical application of serotonin antagonists in the treatment of hypertension].
    Deguchi F; Saito T; Inagaki Y
    Nihon Rinsho; 1989 Sep; 47(9):2058-63. PubMed ID: 2593279
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
    Roald OK; Seem E
    Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serotonin antagonists in the treatment of hypertension].
    Fetkovská N; Brimichová G; Tison P; Dzúrik R
    Cas Lek Cesk; 1984 Mar; 123(11):322-5. PubMed ID: 6367991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.